✦ LIBER ✦

The IV bisphosphonate zoledronic acid [`Zometa'; Novartis] has been approved in the EU

Book ID: 120867423
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2001
Weight: 151 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200112840-00047

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The IV bisphosphonate zoledronic acid [`

The IV bisphosphonate zoledronic acid [`Zometa'; Novartis] has been approved in Switzerland

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Zoledronic acid [`Zometa'; Novartis] has

Zoledronic acid [`Zometa'; Novartis] has received approval in its first market, Canada,

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Ambrisentan has been approved in the EU.

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Serono's somatropin has been denied appr

Serono's somatropin has been denied approval in the EU

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Rabeprazole [`Pariet', Eisai] has been a

Rabeprazole [`Pariet', Eisai] has been approved in all 14 member states of the EU

📂 Article 📅 1998 🏛 Adis International Limited (now part of Wolters Kl ⚖ 116 KB

The bisphosphonate zoledronic acid has a

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation

✍ Andreas Guenther; Sharon Gordon; Markus Tiemann; Renate Burger; Frank Bakker; Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 306 KB

## Abstract Nitrogen‐containing bisphosphonates (N‐BPs) are effective antiosteolytic agents in patients with multiple myeloma. Preclinical studies have also demonstrated that these agents have direct antitumor effects __in vitro__ and can reduce tumor burden in a variety of animal models, although